Chieh-Lung ChengHSIN-AN HOUJhuang J.-Y.CHUNG-WU LINChen, Chien-YuanChien-YuanChenJIH-LUH TANGWEN-CHIEN CHOUTseng M.-H.MING YAOSHANG-YI HUANGBOR-SHENG KOSZU-CHUN HSUSHANG-JU WUWOEI TSAYYAO-CHANG CHENHWEI-FANG TIEN2020-12-092020-12-092011-09-270007-09201532-1827https://scholars.lib.ntu.edu.tw/handle/123456789/525053Angiogenic factors have an essential role in normal and pathologic angiogenesis. However, the clinical implication of angiogenic factor expression in myelodysplastic syndromes (MDS) remains unclear.enangiopoietin; vascular endothelial growth factor; myelodysplastic syndromes; prognosis[SDGs]SDG1[SDGs]SDG3angiopoietin 1; angiopoietin 2; angiopoietin receptor; vasculotropin A; vasculotropin C; acute leukemia; adolescent; adult; aged; article; bone marrow; chronic myelomonocytic leukemia; clinical feature; controlled study; female; follow up; gene expression; human; human cell; karyotype; major clinical study; male; myelodysplastic syndrome; outcome assessment; overall survival; priority journal; prognosis; real time polymerase chain reaction; refractory anemia; refractory anemia with excess blasts; refractory anemia with excess blasts in transformation; refractory anemia with ringed sideroblasts; Adolescent; Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Bone Marrow; Case-Control Studies; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Receptor, TIE-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Young Adult10.1038/bjc.2011.34021878936WOS:000295357900016